VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYNE VYNE Therapeutics Inc.

Post-Mkt 12-11 19:27:41 EST

0.4051

+0.0011

+0.27%

盘后0.4000

-0.0051-1.26%

19:18 EST

High0.4213	Low0.3961	Vol1.01M
Open0.4200	D1 Closing0.4040	Amplitude6.24%
Mkt Cap13.48M	Tradable Cap12.49M	Total Shares33.29M
T/O416.08K	T/O Rate3.29%	Tradable Shares30.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYNE","market":"US","secType":"STK","nameCN":"VYNE Therapeutics Inc.","latestPrice":0.4051,"timestamp":1765486800000,"preClose":0.404,"halted":0,"volume":1013692,"hourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.4051,"latestTime":"19:18 EST","volume":3976,"amount":1592.44263024,"timestamp":1765498687348},"delay":0,"floatShares":30823100,"shares":33286422,"eps":-0.788408,"marketStatus":"Post-Mkt","change":0.0011,"latestTime":"12-11 19:27:41 EST","open":0.42,"high":0.4213,"low":0.3961,"amount":416084.24541564,"amplitude":0.062376,"askPrice":0.42,"askSize":6000,"bidPrice":0.4,"bidSize":28200,"shortable":3,"etf":0,"ttmEps":-0.788408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":0.404,"preHourTrading":{"tag":"盘前","latestPrice":0.399,"preClose":0.404,"latestTime":"09:26 EST","volume":29562,"amount":12067.55900532,"timestamp":1765463176031},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.4051,"latestTime":"19:18 EST","volume":3976,"amount":1592.44263024,"timestamp":1765498687348},"volumeRatio":1.371378,"impliedVol":3.8705,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VYNE/tweets","defaultTab":"tweets","newsList":[{"id":"2584926067","title":"VYNE Therapeutics Q3 Revenue USD 169 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926067","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926067?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:54","pubTimestamp":1763571272,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - VYNE Therapeutics Q3 net income USD -7.28 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:32:33.287 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD7DDsJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2583588238","title":"Vyne Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588238","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588238?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:10","pubTimestamp":1762981811,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc. will hold its Annual Meeting of Stockholders on December 12, 2025, in Bedminster, New Jersey. During the meeting, shareholders will vote on the election of two nominees as Class I directors to serve until the 2028 annual meeting of stockholders or until their successors are elected, and the ratification of the selection of Baker Tilly US, LLP as the company's independent registered public accounting firm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL18YfJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2581380428","title":"VYNE Therapeutics (VYNE) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2581380428","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581380428?lang=en_us&edition=fundamental","pubTime":"2025-11-08 01:56","pubTimestamp":1762538204,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics today and set a price target of $2.00. Ku covers the Healthcare sector, focu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-gets-a-buy-from-td-cowen-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-gets-a-buy-from-td-cowen-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","KUmain","TD","BK4588","BK4207","VYNE","XBI","BK4585","COWN","BK4007","BK4566","XLV","BK4127"],"gpt_icon":0},{"id":"2581095781","title":"VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095781","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095781?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:29","pubTimestamp":1762435771,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48684703/vyne-therapeutics-q3-eps-0-17-misses-0-13-estimate-sales-169-000k-beat-100-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2581900095","title":"VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2581900095","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581900095?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:11","pubTimestamp":1762434680,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $169k vs $121k last year. “Consistent with our focus on growing shareholder value, we have made considerable progress in evaluat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-reports-q3-eps-17c-vs-29c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-reports-q3-eps-17c-vs-29c-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2581093260","title":"VYNE Therapeutics Q3 net loss narrows, strategic review ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093260?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:07","pubTimestamp":1762434439,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics Q3 net loss narrows, strategic review ongoingOverviewVYNE Q3 net loss decreases compared to last yearCompany progressing with strategic review to maximize shareholder valueOutlookVYN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2581093449","title":"Vyne Therapeutics reports third quarter results and updates on pipeline progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093449","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093449?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:05","pubTimestamp":1762434315,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc. reported a net loss of $7.3 million, or $0.17 per share, for the third quarter ended September 30, 2025, compared to a net loss of $12.2 million, or $0.29 per share, for the same period in 2024. Research and development expenses decreased by 48.7% to $5.3 million, primarily due to lower expenses for repibresib and VYN202 following the termination of a Phase 2b trial in nonsegmental vitiligo and reduced clinical expenses, partially offset by a $1.0 million milestone payment for VYN202. General and administrative expenses were $2.7 million, down 8.7% from the prior year. The company reported a cash runway into the first half of 2027, citing previously announced cost reductions. Vyne is continuing a 12-week non-clinical toxicology study for VYN202 and is progressing with a strategic review to evaluate options for maximizing shareholder value, including pipeline opportunities and broader strategic alternatives.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLb19967:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2581004098","title":"BRIEF-VYNE Therapeutics Q3 Revenue USD 169 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004098","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581004098?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434048,"startTime":"0","endTime":"0","summary":"BRIEF-VYNE Therapeutics Q3 Revenue USD 169 Thousand\n\n\nNov 06 (Reuters) - VYNE Therapeutics Q3 net income USD -7.28 million.\n\nQ3 EPS from cont ops USD -0.17","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX1562EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2581933330","title":"Vyne Therapeutics Q3 EPS From Cont Ops USD -0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2581933330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581933330?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX1562EB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2581093830","title":"Vyne Therapeutics Q3 Revenue USD 169 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093830?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX1562EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2567904670","title":"VYNE Therapeutics Faces Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2567904670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567904670?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:36","pubTimestamp":1757709394,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics ( ($VYNE) ) has shared an update. On September 11, 2025, VYNE Therapeutics received a notification from Nasdaq indicating non-com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-faces-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-faces-nasdaq-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","PSQ","QID","NVIW.SI","LU2210149790.SGD","SQQQ","USJW.SI","TSYW.SI","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","BK4588","NQmain","QLD","NDAQ",".IXIC","MNQmain","BK4585","LU0314104364.USD","BK4112","TQQQ","VYNE","IE00B3QW5Z07.USD","LU2210150020.SGD","USAW.SI","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2567675901","title":"Vyne Therapeutics Receives Nasdaq Notification for Non-Compliance with Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2567675901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567675901?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:04","pubTimestamp":1757707449,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc. has announced that it received a notification from The Nasdaq Stock Market LLC regarding non-compliance with Nasdaq Listing Rule 5550, which requires a minimum closing bid price of $1.00 per share. The company's stock has traded below this threshold for 30 consecutive business days. Although this notification does not currently affect the stock's listing on the Nasdaq Capital Market, Vyne Therapeutics must regain compliance by March 10, 2026, to avoid potential delisting. The company is exploring options, including a possible reverse stock split, to meet the requirements. If compliance is not achieved by the deadline, a second 180-day compliance period may be available subject to certain conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL239Sgw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2559954715","title":"VYNE Therapeutics Q2 EPS $(0.13) Beats $(0.22) Estimate, Sales $69.000K Miss $150.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954715","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954715?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:05","pubTimestamp":1755173102,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.22) by 41.7 percent. This is a 40.91 percent increase over losses of $(0.22) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47119008/vyne-therapeutics-q2-eps-0-13-beats-0-22-estimate-sales-69-000k-miss-150-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2559542579","title":"BRIEF-VYNE Therapeutics Q2 EPS From Cont Ops USD -0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2559542579","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559542579?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:00","pubTimestamp":1755172850,"startTime":"0","endTime":"0","summary":"BRIEF-VYNE Therapeutics Q2 EPS From Cont Ops USD -0.13\n\n\nAug 14 (Reuters) - VYNE Therapeutics Q2 basic EPS USD -0.13.\n\nQ2 net income USD -5.755 million\nQ2 revenue USD 69 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX2FB1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2559954293","title":"Vyne Therapeutics Inc - Implements Cost Reductions to Extend Cash Runway to First Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954293?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:00","pubTimestamp":1755172805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX2FB1BF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2559954115","title":"Vyne Therapeutics Q2 Revenue USD 69 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954115?lang=en_us&edition=fundamental","pubTime":"2025-08-14 20:00","pubTimestamp":1755172805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX2FB1BF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2557575804","title":"Vyne Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557575804","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557575804?lang=en_us&edition=fundamental","pubTime":"2025-08-08 23:34","pubTimestamp":1754667259,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to  show a fall in quarterly revenue when it reports  results on Au","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U02RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"gpt_icon":0},{"id":"2555488029","title":"BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2555488029","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555488029?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:57","pubTimestamp":1753963072,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics Inc (VYNE) has an average rating of Hold and mean price target of $4.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VYNE"],"gpt_icon":0},{"id":"2555702588","title":"BUZZ-U.S. STOCKS ON THE MOVE-Electronic Arts, AEP, Peloton Interactive","url":"https://stock-news.laohu8.com/highlight/detail?id=2555702588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555702588?lang=en_us&edition=fundamental","pubTime":"2025-07-31 00:22","pubTimestamp":1753892549,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Electronic Arts, AEP, Peloton InteractiveEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nL6N3TR0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0456854461.SGD","PUMP","IE00BFSS7M15.SGD","V","VFC","WING","ETR","CAPR","LU0719512351.SGD","GB00B4QBRK32.GBP","LU1839511570.USD","HUM","LU0342679015.USD","STX","LRMR","NEM","PANW","BG","LU0444971666.USD","VYNE","FCX","IE00BBT3K403.USD","ETSY","GEHC","SHOO","AEP","GNRC","LU1267930813.SGD","LU0266512127.USD","PPG","EA","LU1823568750.SGD","HOG","SGXZ81514606.USD","LU0823434583.USD","MACW.SI","LU0080751232.USD","KHC","PTON","SCCO","IE00B1BXHZ80.USD","LU2361044865.SGD","HSY"],"gpt_icon":1},{"id":"2555040524","title":"US Stocks Edge Higher; Kraft Heinz Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2555040524","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555040524?lang=en_us&edition=fundamental","pubTime":"2025-07-30 22:16","pubTimestamp":1753885006,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/07/46723168/us-stocks-edge-higher-kraft-heinz-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","KHC","PTHL","SOS","RCKY","BGLC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vynetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0782},{"period":"1month","weight":0.1129},{"period":"3month","weight":0.2797},{"period":"6month","weight":-0.5508},{"period":"1year","weight":-0.847},{"period":"ytd","weight":-0.8794}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.045848},{"month":2,"riseRate":0.375,"avgChangeRate":0.008948},{"month":3,"riseRate":0.375,"avgChangeRate":-0.004279},{"month":4,"riseRate":0.125,"avgChangeRate":-0.181549},{"month":5,"riseRate":0.5,"avgChangeRate":-0.002439},{"month":6,"riseRate":0.125,"avgChangeRate":-0.051065},{"month":7,"riseRate":0.375,"avgChangeRate":-0.153902},{"month":8,"riseRate":0.125,"avgChangeRate":-0.085706},{"month":9,"riseRate":0.5,"avgChangeRate":-0.023153},{"month":10,"riseRate":0.5,"avgChangeRate":0.011012},{"month":11,"riseRate":0.5,"avgChangeRate":-0.029442},{"month":12,"riseRate":0.375,"avgChangeRate":-0.086778}],"exchange":"NASDAQ","name":"VYNE Therapeutics Inc.","nameEN":"VYNE Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VYNE Therapeutics Inc.,VYNE,VYNE Therapeutics Inc.股票,VYNE Therapeutics Inc.股票老虎,VYNE Therapeutics Inc.股票老虎国际,VYNE Therapeutics Inc.行情,VYNE Therapeutics Inc.股票行情,VYNE Therapeutics Inc.股价,VYNE Therapeutics Inc.股市,VYNE Therapeutics Inc.股票价格,VYNE Therapeutics Inc.股票交易,VYNE Therapeutics Inc.股票购买,VYNE Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}